Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy

Gynecologic Oncology

Volumn 119, Issue 2, 2010, Pages 225-231

  Lim, Elaine H ^a   Ng, Shi Len ^a   Li, Jia Liang ^b   Chang, Alexander R ^c   Ng, Joseph ^c   Ilancheran, A ^c   Low, Jeffrey ^c   Quek, Swee Chong ^d   Tay, Eng Hseon ^d  

^a Oncology Research Institute   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Cervical cancer; Cervical dysplasia; CIN; HPV; Methylation; Methylight

Indexed keywords

CYCLIN A1; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; ONCOPROTEIN; PROTEIN HS3ST2; PROTEIN PAX1; PROTEIN TFPI2; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CCNA1 PROTEIN, HUMAN; DAPK1 PROTEIN, HUMAN; GLYCOPROTEIN; HEPARITIN SULFOTRANSFERASE; PAIRED BOX TRANSCRIPTION FACTOR; PAX1 TRANSCRIPTION FACTOR; SULFOTRANSFERASE; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

ARTICLE; CANCER STAGING; DIAGNOSTIC ACCURACY; DNA METHYLATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN METHYLATION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; FEMALE; GENETICS; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; UTERINE CERVIX TUMOR;

APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN A1; DNA METHYLATION; FEMALE; GLYCOPROTEINS; HUMANS; LOGISTIC MODELS; PAIRED BOX TRANSCRIPTION FACTORS; RISK FACTORS; SULFOTRANSFERASES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; DEATH-ASSOCIATED PROTEIN KINASES;

EID: 77957753838     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.07.028     Document Type: Article

References (62)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. D. Solomon, D. Davey, and R. Kurman The 2001 Bethesda System: terminology for reporting results of cervical cytology JAMA 287 2002 2114 2119
3. M.H. Stoler, and M. Schiffman Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study JAMA 285 2001 1500 1505
4. M.H. Stoler, M.D. Vichnin, A. Ferenczy FUTURE I, II, and III Investigators The accuracy of colposcopic biopsy: analyses from the placebo arm of the gardasil clinical trials Int J Cancer May 20 2010 [Epub ahead of print]
5. M. Sideri, F. Schettino, and L. Spinaci Operator variability in disease detection and grading by colposcopy in patients with mild dysplastic smears Cancer 76 1995 1601 1605
6. E.H. Hopman, F.J. Voorhorst, and P. Kenemans Observer agreement on interpreting colposcopic images of CIN Gynecol Oncol 58 1995 206 209
7. J.T. Cox, M. Schiffman, D. Solomon ASCUS-LSIL Triage Study (ALTS) Group Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy Am J Obstet Gynecol 188 2003 1406 1412
8. R.G. Pretorius, W.H. Zhang, and J.L. Belinson Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse Am J Obstet Gynecol 191 2004 430 434
9. J.C. Gage, V.W. Hanson, K. Abbey ASCUS LSIL Triage Study (ALTS) Group Number of cervical biopsies and sensitivity of colposcopy Obstet Gynecol 108 2006 264 272
10. T.C. Wright Jr., L.S. Massad, and C.J. Dunton 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ Am J Obstet Gynecol 197 2007 340 345
11. R. Guido, M. Schiffman, D. Solomon, and L. Burke Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study Am J Obstet Gynecol 188 2003 1401 1405
12. A.G. Ostor Natural history of cervical intraepithelial neoplasia: a critical review Int J Gynecol Pathol 12 1993 186 192
13. M.F. Mitchell, G. Tortolero-Luna, and T. Wright Cervical human papillomavirus infection and intraepithelial neoplasia: a review J Natl Cancer Inst Monogr 21 1996 17 25
14. J.K. Chan, B.J. Monk, and C. Brewer HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3 Br J Cancer 89 2003 1062 1066
15. P.E. Castle, M. Schiffman, C.M. Wheeler, and D. Solomon Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia-Grade 2 Obstet Gynecol 113 2009 18 25
16. L. Gustafsson, and H.O. Adami Natural history of cervical neoplasia: consistent results obtained by an identification technique Br J Cancer 60 1989 132 141
17. M.R. McCredie, K.J. Sharples, and C. Paul Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study Lancet Oncol 9 2008 425 434
18. R.G. Pretorius, P. Peterson, F. Azizi, and R.J. Burchette Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less Am J Obstet Gynecol 195 2006 1260 1265
19. J. Melnikow, J. Nuovo, and A.R. Willan Natural history of cervical squamous intraepithelial lesions: a meta-analysis Obstet Gynecol 92 1998 727 735
20. M.H. Schiffman, H.M. Bauer, and R.N. Hoover Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia J Natl Cancer Inst 85 1993 958 964
21. R.H. Kaufman, E. Adam, and J. Icenogle Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia Am J Obstet Gynecol 176 1997 87 92
22. N. Wentzensen, and M. von Knebel Doeberitz Biomarkers in cervical cancer screening Dis Markers 23 2007 315 330
23. J.T. Horng, K.C. Hu, and L.C. Wu Identifying the combination of genetic factors that determine susceptibility to cervical cancer IEEE Trans Inf Technol Biomed 8 2004 59 66
24. H.W. Haverkos, G. Soon, S.L. Steckley, and W. Pickworth Cigarette smoking and cervical cancer: Part I: a meta-analysis Biomed Pharmacother 57 2003 67 77
25. G.Y. Ho, R. Bierman, L. Beardsley, C.J. Chang, and R.D. Burk Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 338 1998 423 428
26. P.E. Castle, D. Solomon, M. Schiffman, and C.M. Wheeler Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities J Natl Cancer Inst 97 2005 1066 1071
27. A.C. Rodriguez, M. Schiffman, and R. Herrero Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections J Natl Cancer Inst 100 2008 513 517
28. A.P. Feinberg, and B. Vogelstein Hypomethylation distinguishes genes of some human cancers from their normal counterparts Nature 301 1983 89 92
29. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
30. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
31. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042 2054
32. P.W. Laird The power and the promise of DNA methylation markers Nat Rev Cancer 3 2003 253 266
33. N. Wentzensen, M.E. Sherman, M. Schiffman, and S.S. Wang Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science Gynecol Oncol 112 2009 293 299
34. N. Yang, J.J. Eijsink, and A. Lendvai Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings Cancer Epidemiol Biomarkers Prev 18 2009 3000 3007
35. N. Yang, E.R. Nijhuis, and H.H. Volders Gene promoter methylation patterns throughout the process of cervical carcinogenesis Cell Oncol 32 2010 131 143
36. J.H. Kim, Y.D. Choi, and J.S. Lee Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens Gynecol Oncol 116 2010 99 104
37. M. Weber, J.J. Davies, D. Wittig, and Oakeley Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells Nat Genet 37 2005 853 862
38. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
39. H. Cui, M. Cruz-Correa, and F.M. Giardiello Loss of IGF2 imprinting: a potential marker of colorectal cancer risk Science 299 2003 1753 1755
40. T.H. Bestor Transposons reanimated in mice Cell 122 2005 322 325
41. M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps Nat Rev Genet 8 2007 286 298
42. L. Wild, and J.L. Flanagan Genome-wide hypomethylation in cancer may be a passive consequence of transformation Biochim Biophys Acta Apr 14 2010 [Epub ahead of print]
43. M. Ehrlich DNA hypomethylation in cancer cells Epigenomics 1 2009 239 259
44. P. Sova, Q. Feng, and G. Geiss Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis Cancer Epidemiol Biomarkers Prev 15 2006 114 123
45. H.C. Lai, Y.W. Lin, and T.H.M. Huang Identification of novel DNA methylation markers in cervical cancer Int J Cancer 123 2008 161 167
46. S.S. Wang, D.J. Smiraglia, and Y.Z. Wu Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning Cancer Res 68 2008 2489 2497
47. C.A. Eads, K.D. Danenberg, and K. Kawakami MethyLight: a high-throughput assay to measure DNA methylation Nucleic Acids Res 28 2000 E32
48. B.N. Trinh, T.I. Long, and P.W. Laird DNA methylation analysis by MethyLight technology Methods 25 2001 456 462
49. S. Ogino, T. Kawasaki, and M. Brahmandam Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis J Mol Diagn 8 2006 209 217
50. M.W. McIntosh, and M.S. Pepe Combining several screening tests: optimality of the risk score Biometrics 58 2002 657 664
51. C. Stephan, S. Wesseling, T. Schink, and K. Jung Comparison of eight computer programs for receiver-operating characteristic analysis Clin Chem 49 2003 433 439
52. A.K. Virmani, C. Muller, and A. Rathi Aberrant methylation during cervical carcinogenesis Clin Cancer Res 7 2001 584 589
53. K.S. Gustafson, E.E. Furth, and D.F. Heitjan DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis Cancer 102 2004 259 268
54. Q. Feng, A. Balasubramanian, and S.E. Hawes Detection of hypermethylated genes in women with and without cervical neoplasia J Natl Cancer Inst 97 2005 273 282
55. S.L. Kahn, B.M. Ronnett, P.E. Gravitt, and K.S. Gustafson Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests Cancer 114 2008 57 64
56. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
57. J. Paavonen, P. Naud, and J. Salmeron Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
58. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
59. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
60. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
61. N. Perrimon, and M. Bernfield Specificities of heparan sulphate proteoglycans in developmental processes Nature 404 2000 725 728
62. K. Miyamoto, K. Asada, and T. Fukutomi Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers Oncogene 22 2003 274 280